← Back to Search

Procedure

Remote Ischemic Conditioning for Multiple Sclerosis

N/A
Waitlist Available
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
With Primary Progressive Multiple Sclerosis, according to current diagnostic criteria
Screening timed 25-foot walk (average of two trials) of 5.5 seconds or more
Must not have
Patients with known significant hepatic impairment
Patients currently using immune-modulators such as ocrelizumab or hydroxychloroquine
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if a non-pharmaceutical, safe, and tolerable intervention (RIC) can prevent worsening of walking ability in people with primary progressive MS.

Who is the study for?
This trial is for individuals with primary progressive multiple sclerosis (PPMS). Specific eligibility criteria are not provided, but typically participants must meet certain health conditions and cannot have factors that would exclude them from safely participating in the study.
What is being tested?
The trial is testing Remote Ischemic Conditioning (RIC), a non-drug treatment involving repeated cycles of transient limb ischemia. The goal is to see if it can prevent worsening walking ability in PPMS patients by promoting remyelination in the nervous system.
What are the potential side effects?
While specific side effects are not listed, RIC has been considered safe and tolerable in previous stroke trials. Potential side effects may be related to temporary restriction of blood flow during treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My condition is diagnosed as Primary Progressive Multiple Sclerosis.
Select...
It takes me more than 5.5 seconds to walk 25 feet.
Select...
I am between 18 and 65 years old.
Select...
My disability score is between 4.0 and 6.5.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a known liver condition.
Select...
I am currently taking immune-modulating drugs like ocrelizumab or hydroxychloroquine.
Select...
I have increased my dose of Baclofen or Tizanidine during the study.
Select...
I am receiving Botulinum toxin treatment in my leg muscles.
Select...
I am currently taking blood thinners like warfarin or apixaban.
Select...
I am currently taking Fampridine or 4-aminopyridine.
Select...
I cannot or do not want to have MRI scans with gadolinium.
Select...
I have had blood clots in my arms before.
Select...
My MRI scan shows areas that lit up after receiving a contrast dye.
Select...
I have kidney problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Timed 25-foot walk
Secondary study objectives
MRI measure of remyelination
Nine Hole Peg Test
SDMT (Single digit modalities test)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RICExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Remote ischemic conditioning
2017
Completed Phase 2
~7350

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
809 Previous Clinical Trials
886,315 Total Patients Enrolled
9 Trials studying Multiple Sclerosis
371 Patients Enrolled for Multiple Sclerosis
~30 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top